Advanced Enzyme Technologies Limited (ADVENZYMES)
🎯 Key Takeaways
- Advanced Enzyme Technologies Limited is a mature, cash-generative player in the specialty enzymes space with stable profitability and low leverage, currently navigating a phase of incremental growth and shareholder return focus. The company demonstrates consistent operational efficiency with healthy operating margins and strong returns on capital, but faces headwinds from flat revenue growth and modest profitability pressures.
- Revenue grew 18.3% QoQ to ₹203 in Q4FY26.
- ⚠️ Revenue growth has slowed in recent quarters, with YoY growth flattening despite stable margins, raising concerns about market saturation or demand so
📖 The Story
Advanced Enzyme Technologies Limited is a mature, cash-generative player in the specialty enzymes space with stable profitability and low leverage, currently navigating a phase of incremental growth and shareholder return focus. The company demonstrates consistent operational efficiency with healthy operating margins and strong returns on capital, but faces headwinds from flat revenue growth and modest profitability pressures. Management is prioritizing capital allocation through dividends and strategic stakeholder engagement, signaling confidence in steady cash flows.
📰 What's Happening
In Q4FY26, the company reported revenue of ₹203 crore with operating profit of ₹71 crore and net profit of ₹45 crore, reflecting sequential improvement from ₹186 crore revenue and ₹40 crore net profit in Q1FY26. Management highlighted stable demand across key sectors including pharmaceuticals and agrochemicals, with no major new order announcements but consistent execution on existing contracts. The 37th Annual General Meeting scheduled for July 31, 2026, will focus on reappointing directors Kabra and Shah, approving the audit report, and sanctioning a final dividend of ₹1.35 per share. A key corporate action involves finalizing related party transactions with JC Biotech Private Limited, indicating ongoing internal resource allocation decisions.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 |
| Operating Profit | 58 | 52 | 63 | 54 | 65 | 70 | 69 | 71 |
| OPM % | 33.1% | 29.0% | 32.7% | 27.3% | 30.4% | 32.5% | 28.7% | 31.1% |
| Net Profit | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 |
| EPS | ₹3.05 | ₹2.94 | ₹3.36 | ₹2.37 | ₹3.57 | ₹3.87 | ₹3.80 | ₹3.84 |
Revenue has shown a steady upward trend from ₹146 crore in Q2FY25 to ₹203 crore in Q4FY26, with operating margins holding firm above 30% despite macroeconomic volatility. Profitability remains resilient, with net profit rising from ₹33 crore in Q2FY25 to ₹45 crore in Q4FY26, driven by operational efficiency rather than scale alone. The company has improved its operating cash flow trajectory, with OCF reaching ₹163 crore in FY21 and maintaining strong cash generation, though recent quarterly OCF data is not provided. Management has not cited margin compression or cost pressures in filings, suggesting cost discipline is intact.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or margin expectations in the latest filings, but the consistent reappointment of directors and focus on dividend policy suggest confidence in sustained profitability. The company continues to emphasize governance standards, as evidenced by digital AGM arrangements and compliance with SEBI disclosure norms. No new strategic initiatives or expansion plans were disclosed in the recent filings, indicating a focus on operational stability rather than aggressive growth.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2024-2025 | 2025-2026 | 2025-2026 | 2025-2026 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 |
| Reserves | 1,398 | — | 1,462 | — | 1,610 |
| Borrowings | 22 | — | 20 | — | 21 |
| Total Liabilities | 153 | — | 158 | — | 156 |
| Fixed Assets | 293 | — | 284 | — | 276 |
| Investments | 480 | — | 529 | — | 584 |
| Total Assets | 1,621 | — | 1,692 | — | 1,839 |
The balance sheet shows a strong equity base of ₹22 crore with substantial reserves of ₹1,610 crore and minimal borrowings of ₹21 crore, resulting in a near-zero debt-to-equity ratio of 0.01. This conservative capital structure supports financial flexibility and reduces interest burden, allowing the company to fund operations and dividends without external financing. The growth in reserves reflects retained earnings from consistent profitability, reinforcing a low-risk financial profile.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 | 2020-2021 |
|---|---|---|
| Operating | +81 | +163 |
| Investing | +4 | -26 |
| Financing | -18 | -26 |
| Net Cash Flow | — | — |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Revenue growth has slowed in recent quarters, with YoY growth flattening despite stable margins, raising concerns about market saturation or demand softness. 2. The company’s heavy reliance on a few key sectors — pharmaceuticals and agrochemicals — exposes it to regulatory and demand volatility. 3. Despite strong reserves, the lack of new capital investment announcements may limit future growth scalability. 4. Dividend payout remains high relative to net profit, which could strain cash flows if profitability dips unexpectedly.
📋 Recent Filings
-
share transfer 14 July 2026Advanced Enzyme Technologies Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming demater...
-
🔴 annual report 8 July 2026Advanced Enzyme Technologies announced that shareholders without registered email addresses will receive a link and QR code to access the Integrated A...
-
🔴 annual report 8 July 2026Advanced Enzyme Technologies Limited announced its 37th Annual General Meeting on July 31, 2026, via video conference, to transact ordinary and specia...
-
🟡 Board Meeting 3 July 2026Advanced Enzyme Technologies Limited announced that its 37th Annual General Meeting will be held on July 31, 2026, via video conference, with a record...
-
🔴 Corporate Action 3 July 2026Advanced Enzyme Technologies Limited announced that its 37th Annual General Meeting will be held on July 31, 2026, via video conference, with a record...
-
Financial Results 25 June 2026Advanced Enzyme Technologies Limited announced that its trading window will close on July 1, 2026, and remain closed for 48 hours following the releas...
-
regulation 31 12 June 2026Advanced Enzyme Technologies Limited disclosed under SEBI Takeover Regulations that promoter Chandrakumar Laxminarayan Rathi and Persons Acting in Con...
-
🟡 Board Meeting 11 June 2026Advanced Enzyme Technologies announced that Independent Director Ms. Rajshree Patel (DIN 08761022) will cease to be a director effective June 11, 2026...
-
🔴 Corporate Action 6 June 2026Advanced Enzyme Technologies announced an additional ₹2.5 million investment in its wholly owned subsidiary Advanced Nutrazyme Private Limited through...
-
regulation 31 5 June 2026Advanced Enzyme Technologies Limited promoter Vasant Rathi disclosed on April 7, 2026, that he and related parties have not created new encumbrances o...
🧠 Analyst's Read
Advanced Enzyme Technologies operates as a stable, low-debt specialty chemical player with consistent margins and strong cash generation, but its near-term growth appears limited to incremental improvements. Investors should monitor quarterly revenue trends and any future strategic announcements beyond dividend policy to assess whether the company can reignite growth. The current trajectory reflects a mature business prioritizing returns over expansion, making it suitable for income-focused, low-volatility portfolios but less compelling for growth seekers.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ADVENZYMES files new disclosures
Track ADVENZYMES filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ADVENZYMES — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research